Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
701-720 of 847 trials

ALS Treatment: Masitinib with Riluzole

We are studying whether adding masitinib to Riluzole helps improve outcomes for people with Amyotrophic Lateral Sclerosis. This trial will assess its safety and effectiveness compared to a placebo.

Amyotrophic Lateral Sclerosis6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Multiple Sclerosis: IMU-838 Treatment Study

We are investigating the effects of a new medication, IMU-838, on disease activity in people with relapsing-remitting multiple sclerosis. This study aims to understand how well it works and how safe it is compared to a placebo.

Relapsing-Remitting Multiple Sclerosis3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Setmelanotide for ROHHAD Syndrome

We are studying the effects of setmelanotide on hypothalamic function and related symptoms in patients with ROHHAD syndrome. This trial aims to understand how the treatment may improve various health aspects over time.

ROHHAD Syndrome1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteEndocrinologyInternal Medicine

Pulmonary Arterial Hypertension: Inhaled GB002 Study

We are evaluating the long-term safety and effects of an inhaled medication for people with pulmonary arterial hypertension. The study aims to see if it helps improve exercise capacity and overall well-being.

Pulmonary Arterial Hypertension>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPulmonology

Nivolumab for ALK+ Anaplastic Large Cell Lymphoma

We are studying the effects of nivolumab in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma. This trial looks at its effectiveness for those with progressive disease and as a follow-up treatment for those in remission.

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Parkinson's Disease: CVN424 Study

We are testing a new medication, CVN424, for people with Parkinson's disease to see if it helps reduce OFF time and improve overall motor function. The study also aims to evaluate its safety and effects on quality of life.

Parkinson's Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Chronic Rhinosinusitis with Nasal Polyps: Itepekimab Study

We are investigating whether itepekimab can help adults with chronic rhinosinusitis and nasal polyps by reducing polyp size and nasal congestion. This study will also look at its effects on overall symptoms and quality of life.

Chronic Rhinosinusitis with Nasal PolypsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngologyPulmonology

Hypochondroplasia: Infigratinib for Growth

We are investigating whether infigratinib can help children aged 3 to 11 with hypochondroplasia grow taller and improve their overall health. The study will also look at the safety of this new treatment.

Hypochondroplasia>2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteInternal MedicinePediatrics

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Solid Tumors: Valemetostat Tosylate with DXd ADCs

We are studying a new combination treatment for patients with solid tumors to evaluate its safety and effectiveness. This trial aims to find better options for managing cancer.

Solid TumorSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

Neovascular Age-Related Macular Degeneration: Port Delivery System with Ranibizumab

We are studying a new delivery system for ranibizumab in patients with neovascular age-related macular degeneration. The goal is to see how well it works and how it affects patients' treatment experiences.

Neovascular Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

Crohn's Disease: SAR442970 Study

We are investigating the effects of a new medication, SAR442970, on adults with moderate to severe Crohn's disease. The study aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Citalopram for Reflux Hypersensitivity and Functional Heartburn

We are studying whether adding citalopram to existing treatments helps patients with reflux hypersensitivity or functional heartburn who still have symptoms. This trial aims to improve symptom relief for those not fully responding to current therapies.

Gastroesophageal Reflux Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPsychiatry

CIDP: Riliprubart Treatment Study

We are studying the long-term safety and effectiveness of riliprubart for individuals with chronic inflammatory demyelinating polyneuropathy. This trial will help us understand how well it works in improving disability and strength.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Mucopolysaccharidosis Type IIIA: JR-441 Infusions

We are evaluating the safety and potential effectiveness of JR-441 infusions for patients with mucopolysaccharidosis type IIIA. This study aims to explore how well this treatment works for this rare condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicinePediatrics

Golcadomide for Brain Lymphoma: A Phase 2 Study

We are studying the effectiveness of golcadomide in patients with relapsed or refractory large B-cell lymphoma in the brain. The goal is to see if it can help achieve remission and improve overall health.

Diffuse Large B-Cell LymphomaSecondary Central Nervous System LymphomaRelapsed Primary Large B-Cell Lymphoma of the Central Nervous System1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Menstrual Migraine: Rimegepant Study

We are investigating whether Rimegepant can help prevent menstrual migraines in women aged 18 to 45. This study compares its effects to a placebo to see if it reduces migraine frequency and improves quality of life.

Menstrual Migraine6-12 monthsConfirmation phase (III)≤5 visitsPost-Trial Drug AccessStandard MedicinesGynecology and ObstetricsNeurology

Chronic Hepatitis Delta: BJT-778 vs Bulevirtide

We are studying a new treatment called brelovitug for chronic hepatitis delta infection to see if it works better and is safer than the current treatment, bulevirtide. We also want to understand how it affects patients' quality of life.

Chronic Hepatitis D Infection1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHepatologyInfectious Diseases

Multiple System Atrophy: Lu AF82422 Study

We are testing the medication Lu AF82422 to see if it can slow disease progression in people with Multiple System Atrophy. The study will also look at its effects on overall health and quality of life.

Multiple System Atrophy1-2 yearsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Ovarian Cancer: Mirvetuximab Soravtansine Study

We are evaluating different dosing schedules of mirvetuximab soravtansine for patients with advanced ovarian, peritoneal, or fallopian tube cancers. This study aims to find the safest and most effective way to administer the treatment.

Advanced Ovarian and Fallopian Tube Cancer6-12 monthsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology